MUMBAI, India — Lupin Ltd. plans to buy Gavis Pharmaceuticals LLC and Novel Laboratories Inc. in an $880 million deal.

Lupin said Thursday that the acquisition will boost its scale in the U.S. generic drug market and broadens its pipeline in dermatology, controlled-substance products, and other high-value and niche generics.

In addition, Gavis brings a highly skilled, U.S.-based research and development organization that would complement Lupin’s Coral Springs, Fla., inhalation R&D center, Lupin noted, adding that Gavis’ New Jersey-based manufacturing facility would become Lupin’s first manufacturing site in the United States.

Gavis had fiscal 2014 sales of $96 million  and has more than 250 New Jersey-based employees. Currently, Gavis has 66 Abbreviated New Drug Application (ANDA) filings pending approval with the Food and Drug Administration and a pipeline of more than 65 products under development, according to Lupin, which reported that Gavis’ pending filings address a market of about $9 billion.

“This is a pivotal acquisition for Lupin as it aligns with our goal to expand and deepen our U.S. presence. GAVIS has a strong track record of delivering highly differentiated products in a short time and is poised for continued strong growth as it delivers on its existing pipeline,” stated Vinita Gupta, chief executive officer of Lupin Ltd. “Gavis’ capabilities and pipeline are an excellent complement to Lupin. The acquisition accelerates Lupin’s entry into niche areas like controlled substances and dermatology. We are confident that Lupin’s proven commercialization capabilities, vertically integrated manufacturing operations and supply chain strengths will accelerate Gavis’ growth.”

The transaction has been unanimously approved by the boards of directors of Lupin and Gavis. The combined company will have a portfolio of 101 in-market products, 164 cumulative filings pending approval and a deep pipeline of products under development for the United States. Lupin said the acquisition creates the fifth-largest portfolio of ANDA filings with the FDA, addressing a $63.8 billion market.

Lupin is the fifth-largest generics player in the United States and the third-largest Indian pharmaceutical company by sales.

“This is a time of globalization for the specialty pharmaceutical industry, and Gavis is well-positioned to capitalize on this exciting opportunity,” commented Veerappan Subramanian, founder and CEO of Somerset, N.J.-based Gavis. “Joining forces with Lupin, a truly global player, will help realize our vision of building a broader, research-based, high-value, specialty business through organic growth. I am confident that the combined entity will be a powerhouse in the U.S. specialty space and will significantly enhance Lupin’s U.S. platform.”